Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
Caplin Point Laboratories announced a final dividend of ₹4 per share (200% on a face value of ₹2) for the financial year 2025-26, with a record date of September 18, 2026. The company will also hold its 35th Annual General Meeting (AGM) on September 25, 2026, via video conferencing. During the AGM, the adoption of FY2025-26 financials, declaration of the final dividend, and ratification of an interim dividend (totaling ₹8 per share for the year) will be discussed. Additionally, approvals for the re-appointment of Dr. Sridhar Ganesan as Managing Director and Mr. D. Muralidharan as Whole Time Director are on the agenda. The company also submitted its Business Responsibility and Sustainability Report (BRSR) for FY2025-26, highlighting 36.65% renewable energy usage and ₹4.70 Crores spent on CSR.
As of September 18, 2026, Caplin Point Laboratories' stock has shown varied returns across different periods. It has returned 6% in the last trading day, 9% in the last month, and 18% in the last year. Notably, it has achieved a 67% return in the last six months and a 53% year-to-date return. Technical indicators show a bullish trend on daily, weekly, and monthly timeframes, with the Supertrend indicator at 2508.16 on a daily basis. Key support levels are observed around ₹2675.0, ₹2652.4, and ₹2624.5, while a resistance level is noted at ₹2877.3.
Caplin Point Laboratories has an annualized volatility of 0.39 and an Average True Range (ATR) of 3.93% as of September 18, 2026. The current drawdown is -3%, with a maximum drawdown recorded at -42%. The downside deviation stands at 0.26.
As of 18 Sept 2026, 03:30 pm
Showing 3 of 31 candles
Recent drawdown or price variability is high enough to warrant closer monitoring.
Primary driver: Price swings are higher than typical
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
Trading activity was substantially higher than usual and the price closed lower.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
Latest complete financial results and comparative quarterly trends.
Exchange disclosures and regulatory announcements for Caplin Point Laboratories.
SERIES:EQ ; PURPOSE:DIVIDEND - RS 4 PER SHARE ; FACE VALUE:2 ; RECORD DATE:18-Sep-2026 ; BOOK CLOSURE START DATE:- ; BOOK CLOSURE END DATE:-
Caplin Point Laboratories Limited will hold its 35th Annual General Meeting on September 25, 2026, at 10:00 AM IST via video conferencing. The company has sent letters to shareholders without registered email addresses, providing a weblink to access the Annual Report and AGM Notice for the financial year 2025-26.
Caplin Point Laboratories Limited notified the BSE and NSE on September 04, 2026, regarding the publication of newspaper advertisements in Financial Express and Maalai Malar concerning its 35th Annual General Meeting. The meeting is scheduled to be held via Video Conferencing/Other Audio-Visual Means on Friday, September 25, 2026, at 10:00 a.m. (IST), with e-voting information included in the notice. This disclosure was made pursuant to Regulations 30 and 47 of the SEBI Listing Regulations and Section 108 of the Companies Act, 2013.
Caplin Point Laboratories Ltd. will hold its 35th AGM on September 25, 2026, via video conferencing to adopt FY2025-26 financials, declare a final dividend of ₹4 per share (200%), and ratify an interim dividend of ₹4 per share, totaling ₹8 (400%) for the year. The meeting also seeks approval for the re-appointment of Dr. Sridhar Ganesan as Managing Director for two years from August 25, 2026, at a salary of ₹55,20,000 per annum; continuation of Mr. C. C. Paarthipan as Chairman and Non-Executive Director past age 75; and appointment of Mr. D. Muralidharan as Whole Time Director for two years from August 12, 2026, at a salary of ₹62,37,600 per annum, while he continues as CFO without additional compensation.
Caplin Point Laboratories Limited submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the BSE and NSE on September 3, 2026. The Board expanded the CSR Committee's mandate to include sustainability oversight on August 12, 2026, renaming it the 'CSR and Sustainability Committee' and appointing Dr. R. Nagendran as chair. During FY 2025-26, the company achieved 36.65% renewable energy usage, conserved 46,464.46 KL of freshwater, spent ₹4.70 Crores on CSR, and secured limited assurance from M/s Alagar & Associates LLP for its core disclosures.
Caplin Point Laboratories Limited has informed the Exchange about Notice of Shareholders Meeting for Annual General Meeting to be held on 25-Sep-2026 |SUBJECT: Notice Of Shareholders Meetings-XBRL
Caplin Point Laboratories Limited will hold its 35th Annual General Meeting on September 25, 2026, via video conference. Agenda items include adopting audited financials for FY ended March 31, 2026, declaring a final dividend of Rs 4 per share (200%) and ratifying an interim dividend of Rs 4 per share, aggregating to Rs 8 per share (400%) for the year. Dr. Sridhar Ganesan will be re-appointed as Managing Director from August 25, 2026 to August 24, 2028, and Mr. D Muralidharan will be appointed as Whole Time Director from August 12, 2026 to August 11, 2028. The meeting also covers the re-appointment of Dr. Sridhar Ganesan as a director retiring by rotation and the continuation of Mr. C. C. Paarthipan as Chairman and Non-Executive, Non-Independent Director.
On September 2, 2026, Caplin Point Laboratories Limited responded to a National Stock Exchange inquiry dated September 1, 2026, regarding a significant increase in its equity share trading volume. The company confirmed full compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, stating that all material events and price-sensitive information have been disclosed. Caplin Point attributed the volume surge to market-driven factors and affirmed it is unaware of any specific reasons contributing to the activity.
Recent market and company developments associated with Caplin Point Laboratories.
Trade Spotlight
Indian stock market indices, Sensex and Nifty 50, are expected to open higher on 4 September, following positive global cues. Previous sessions saw declines, but easing bond yields may boost risk assets. Cautious trading is projected ahead of key US nonfarm payrolls data.
Stocks to buy, Stock picks, Stocks to trade, trading views, Mphasis, Caplin Point Laboratories, Engineers India, Mphasis shares, Caplin Point shares, Engineers India shares, Mphasis share price, Caplin Point share price, Engineers India share price, Mphasis stock price, Caplin Point stock price, Engineers India stock price, Mphasis target price, Caplin Point target price, Engineers India target price
All the three Pharma stocks in focus today, Gland Pharma, Caplin Point and Nephrocare Health, have risen between 50% to 70% so far this year.
Buzzing Stocks
Shares of Steel Authority of India (SAIL) barred from fresh F&O positions on 24 August 2026.
Indian equity markets closed largely unchanged on Friday, August 21, after a volatile trading session. Several companies, including Reliance Industries and Bank of Baroda, reported significant corporate developments. Power Grid Corporation and Jubilant Pharmova also announced key project wins and regulatory approvals. NATCO Pharma and Caplin Point Laboratories received observations from the US FDA after inspections. Mobile manufacturing stocks are expected to gain attention following a new gover...
RIL shareholders approved resolutions on Aug 20, 2026. Caplin Point, NATCO Pharma, and Choksi Labs received US FDA Form 483 observations. Mobile & EMS stocks in focus after new manufacturing scheme.
Comprehensive Section Breakdown for Caplin Point Laboratories
Strategic Vision: Pharmaceutical company engaged in R&D, manufacturing, and marketing.
• Global product registrations across diverse geographies
• USFDA/EU-GMP approved injectable facility
• Extensive product portfolio covering numerous therapeutic sections
Category: Manufacturing
Production of a wide range of pharmaceutical formulations, covering over 36 therapeutic sections with more than 650 products.
Category: Manufacturing
Manufacturing of Active Pharmaceutical Ingredients (APIs) as part of its pharmaceutical product offerings.
Category: B2B Services
Engagement in clinical research activities related to pharmaceutical product development.
Core Thesis: The company leverages its manufacturing capabilities and global registrations to market pharmaceutical products across diverse geographies.
• Global Market Access: The company has over 4000 product registrations worldwide and a brand marketing presence in Latin America and Francophone Africa. • Regulatory Compliance: Operates a USFDA/EU-GMP approved injectable facility, enabling service to highly regulated markets. • Diverse Product Portfolio: Offers more than 650 pharmaceutical formulations across over 36 therapeutic sections.